Changeflow GovPing Healthcare & Life Sciences Multi-Partite CRISPR Editors, High-Throughput D...
Routine Notice Added Final

Multi-Partite CRISPR Editors, High-Throughput Discovery Methods

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

US Patent Application US20260109972A1, filed November 9, 2023, has been published by the USPTO, disclosing multi-partite CRISPR-based editor compositions and high-throughput methods for discovering polypeptides with editing activity. Inventors include Luke A. Gilbert, Greg Pommier, Jonathan Weissman, and Caroline Wilson. The publication makes the application's technical disclosure publicly accessible as prior art.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.

What changed

The USPTO has published patent application US20260109972A1, which discloses methods for determining whether candidate polypeptides in a library exhibit editing activity using multi-partite CRISPR-based editors. The disclosed methods involve expressing in cells a library of expression cassettes encoding polypeptides that include a first editing domain, a nuclease-deficient RNA-guided endonuclease domain, and a second editing domain, together with a guide RNA expression cassette targeting a sequence of interest.

Affected parties such as patent applicants, biotechnology researchers, and genome editing companies should monitor this publication as prior art that may affect freedom-to-operate analyses and competitive patent landscapes in the CRISPR gene editing space. No compliance obligations arise solely from the publication of a patent application.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

High-Throughput Discovery of Multi-Partite CRISPR-Based Editors

Application US20260109972A1 Kind: A1 Apr 23, 2026

Inventors

Luke A. Gilbert, Greg Pommier, Jonathan Weissman, Caroline Wilson

Abstract

Provided are methods for determining that a candidate polypeptide in a library of polypeptides has editing activity comprising expressing in a plurality of cells: a library of first expression cassettes each comprising a nucleic acid encoding a polypeptide wherein each polypeptide in the library comprises, a first editing domain, a first linker, a nuclease-deficient RNA guided endonuclease domain, a second linker, and a second editing domain; and a second expression cassette comprising a nucleic acid encoding a guide RNA directed to a target of interest, wherein said first and second expression cassettes are expressed in the plurality of cells; separating the plurality of cells based on the expression level of the target of interest; extracting genomic DNA (gDNA) from the plurality of cells; and sequencing the gDNA of cells that have a high level expression or a low level of expression of the target of interest.

CPC Classifications

C12N 15/1082

Filing Date

2023-11-09

Application No.

19127007

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260109972A1

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Researchers and research institutions
Industry sector
3254.1 Biotechnology
Activity scope
Patent application filing Intellectual property registration Gene editing research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!